Smol International Releases 2022 Half-Year Performance Report

Aug.24.2022
Smol International Releases 2022 Half-Year Performance Report
Semiconductor company SMIC reported solid H1 2022 earnings of CNY 56.5 billion, driven by innovation and diversification.

On August 24th, Semiconductors International (06969) released its financial report for the first half of 2022. The company reported a revenue of RMB 5.65 billion and an adjusted net profit of RMB 1.44 billion.


In the first half of 2022, Chen Zhiping, Chairman of the Board of Directors of Sumitomo International, expressed the company's commitment to long-term thinking in the face of an ever-changing and challenging external environment. The company will continue to invest in the future and adhere to its long-term philosophy. Scientific and technological innovation is the driving force of Sumitomo's development, and only by adhering to innovation can the company build long-term competitiveness and create long-term value for the country, customers, employees, and shareholders.


The US market helps clients become number one, while the Chinese market actively supports regulation.


The financial report reveals that from January to June 2022, Simore's operating income was 5.65 billion and adjusted net profit was 1.44 billion.


Behind the stable revenue is SMOORE's active layout in the electronic atomization market and the diversity of its income distribution. According to data, in the first half of the year, SMOORE's enterprise customer business (ODM) and retail customer business (APV) grew rapidly in Europe. In terms of revenue for the first half of the year, the proportion of income from countries and regions outside of China and the United States was 39%, an increase of 16 percentage points compared to the same period last year, which was 23%.


In the US market, Smoore, with its technological and manufacturing advantages, has become a leading manufacturer of ENDS (electronic nicotine delivery systems) that assists many customers to pass PMTA (premarket tobacco product application). Additionally, Smoore has helped its customers gain market share by offering reasonable prices. It is expected that the company will maintain stable and healthy orders throughout the second half of the year.


In the Chinese market, Smoore supports regulatory policies. The current planning and regulation by the National Tobacco Monopoly Administration marks a new starting point for industry development in accordance with regulations. Smoore strictly adheres to regulatory requirements and actively applies for tobacco monopoly production licenses. Currently, three subsidiaries have already been granted production licenses. Smoore will continue to strengthen research and development of products that meet national standards to meet regulatory requirements and provide consumers with a better experience. At the same time, it will ensure the delivery of products that meet national standards from the manufacturing end.


Research and development investment has increased significantly by 156%, as the company continues to focus on internal innovation to build its core competitiveness.


Chen Zhiping stated that on the path of creating a globally leading atomization technology platform, it is impossible to have a completely smooth journey. We will continue to believe in the promising future of atomization technology, persist in invention and innovation, and remain committed to a long-term strategy.


As a result, SiMoEr has been increasing their research and development investment according to their planned schedule. They are focusing particularly on areas such as basic research, new materials research, and atomization medical treatment in order to improve their talent density, establish a global research and development system, and build their core competitiveness. In the first half of the year, their research and development expense was 604 million yuan, which is a 156% increase compared to the same period last year.


During the first half of the year, 14 basic research institutes were put into operation globally, with several important scientists and hundreds of masters and doctoral students from renowned universities joining the company. As of June 30th, there were 1,472 R&D experts at SMIC, accounting for over 40% of the total R&D personnel.


Top talent joining has enabled Semler to further cultivate core technology and build a core patent barrier. Currently, there are 4,337 patent applications globally, with 929 newly added applications in the first half of this year. In April of this year, "Semler's launch of a 337 rights protection investigation in the US" was consecutively selected as one of the top ten intellectual property events in Guangdong Province and Shenzhen City in 2021.


Medical atomization products smoothly enter domestic approval channel.


In the field of medical nebulization, Simoer has established a wholly-owned subsidiary in the United States to focus on the research and development of respiratory drug products, providing relief for patients with asthma and chronic obstructive pulmonary disease. Currently, they have reached an agreement with one of the world's largest pharmaceutical manufacturing companies to develop two nebulized drugs. If the products are approved smoothly, they are expected to be launched in the next few years.


In addition, Simoer's first domestic research and development of a nebulizer device is currently going through the approval process in China.


In the first half of the year, exports generated 3.955 billion yuan in foreign exchange earnings. The four major directions for reducing carbon emissions were announced as a priority.


As a "dream chaser with love", Si Moer continuously responds to public expectations and practices corporate social responsibility through concrete actions.


In the first half of the year, SMIC generated 3.955 billion USD in foreign exchange earnings by exporting to overseas markets. To address the challenging situation of over 10 million university graduates in 2022, SMIC has established deep school-enterprise cooperation relationships with 15 colleges and universities, cultivating and supplying over 1,000 skilled workers to the industry. Additionally, SMIC is actively implementing talent management programs, such as "SMIC model talent" and "SMIC skilled talent," targeting graduates in 2022 and 2023.


In addition, as the first vaporization technology company to list a carbon neutrality schedule, Simoer has released its carbon reduction targets and plans to achieve carbon neutrality within scopes 1 and 2 by 2050. Data shows that in 2021, Simoer has achieved a year-on-year decrease in greenhouse gas emissions density of about 16% and a year-on-year reduction in water consumption density of about 9.4%.


During the first half of the year, semiconductor company SMIC was able to maintain its A-grade rating in ESG evaluations published by MSCI, the world's largest index provider. Additionally, SMIC was awarded five major prizes, including the award for corporate governance (ESG), in the 2022 Asia Management Team selection.


This article includes excerpts or reprints of information from third-party sources. Copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reprint must contact the author. Please do not directly repost.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey Councillor Gordon Hepner presented a notice of motion calling on council to “wage war on vaping” by strengthening controls on the sale of vaping products in the city, citing vaping as a “serious health concern,” especially among youth. Hepner said the motion directs staff to bring back the “most restrictive legally supportable” package from the City’s 2019 bylaw work to materially reduce where and how vape products can be sold, including licensing controls and enforcement.
Feb.10 by 2FIRSTS.ai
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
Arizona e-cigarette shops ordered to pay $460,000 for selling tobacco and nicotine products to minors
Arizona e-cigarette shops ordered to pay $460,000 for selling tobacco and nicotine products to minors
Arizona Attorney General Kris Mayes announced Pro Source Supply LLC, Pro Source Vapes LLC, Pro Source CBD LLC, and owner Timothy Kell must pay $460,000 in restitution tied to a lawsuit filed last year alleging illegal sales of tobacco and nicotine products to underage buyers.
Jan.07 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24